Literature DB >> 22689735

Evidence-based guideline update: medical treatment of infantile spasms. Report of the Guideline Development Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

C Y Go1, M T Mackay, S K Weiss, D Stephens, T Adams-Webber, S Ashwal, O C Snead.   

Abstract

OBJECTIVE: To update the 2004 American Academy of Neurology/Child Neurology Society practice parameter on treatment of infantile spasms in children.
METHODS: MEDLINE and EMBASE were searched from 2002 to 2011 and searches of reference lists of retrieved articles were performed. Sixty-eight articles were selected for detailed review; 26 were included in the analysis. RECOMMENDATIONS were based on a 4-tiered classification scheme combining pre-2002 evidence and more recent evidence.
RESULTS: There is insufficient evidence to determine whether other forms of corticosteroids are as effective as adrenocorticotropic hormone (ACTH) for short-term treatment of infantile spasms. However, low-dose ACTH is probably as effective as high-dose ACTH. ACTH is more effective than vigabatrin (VGB) for short-term treatment of children with infantile spasms (excluding those with tuberous sclerosis complex). There is insufficient evidence to show that other agents and combination therapy are effective for short-term treatment of infantile spasms. Short lag time to treatment leads to better long-term developmental outcome. Successful short-term treatment of cryptogenic infantile spasms with ACTH or prednisolone leads to better long-term developmental outcome than treatment with VGB. RECOMMENDATIONS: Low-dose ACTH should be considered for treatment of infantile spasms. ACTH or VGB may be useful for short-term treatment of infantile spasms, with ACTH considered preferentially over VGB. Hormonal therapy (ACTH or prednisolone) may be considered for use in preference to VGB in infants with cryptogenic infantile spasms, to possibly improve developmental outcome. A shorter lag time to treatment of infantile spasms with either hormonal therapy or VGB possibly improves long-term developmental outcomes.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22689735      PMCID: PMC3369510          DOI: 10.1212/WNL.0b013e318259e2cf

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  40 in total

1.  The Japanese scheme of ACTH therapy in West syndrome.

Authors:  Yukio Fukuyama
Journal:  Epilepsia       Date:  2010-10       Impact factor: 5.864

2.  A European perspective—comments on "Infantile spasms: a U.S. consensus report".

Authors:  Raili Riikonen
Journal:  Epilepsia       Date:  2010-10       Impact factor: 5.864

3.  Outcomes in treatment of infantile spasms with pulse methylprednisolone.

Authors:  John R Mytinger; Mark Quigg; William C Taft; Marcia L Buck; Robert S Rust
Journal:  J Child Neurol       Date:  2010-02-08       Impact factor: 1.987

4.  Vigabatrin for the treatment of infantile spasms: final report of a randomized trial.

Authors:  Roy D Elterman; W Donald Shields; Richard M Bittman; Sarah A Torri; Stephen M Sagar; Stephen D Collins
Journal:  J Child Neurol       Date:  2010-04-19       Impact factor: 1.987

5.  Randomized trial of vigabatrin in patients with infantile spasms.

Authors:  R D Elterman; W D Shields; K A Mansfield; J Nakagawa
Journal:  Neurology       Date:  2001-10-23       Impact factor: 9.910

Review 6.  Infantile spasms: a U.S. consensus report.

Authors:  John M Pellock; Richard Hrachovy; Shlomo Shinnar; Tallie Z Baram; David Bettis; Dennis J Dlugos; William D Gaillard; Patricia A Gibson; Gregory L Holmes; Douglas R Nordl; Christine O'Dell; W Donald Shields; Edwin Trevathan; James W Wheless
Journal:  Epilepsia       Date:  2010-10       Impact factor: 5.864

Review 7.  Epidemiological data of West syndrome in Finland.

Authors:  R Riikonen
Journal:  Brain Dev       Date:  2001-11       Impact factor: 1.961

8.  The United Kingdom Infantile Spasms Study (UKISS) comparing hormone treatment with vigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial.

Authors:  Andrew L Lux; Stuart W Edwards; Eleanor Hancock; Anthony L Johnson; Colin R Kennedy; Richard W Newton; Finbar J K O'Callaghan; Christopher M Verity; John P Osborne
Journal:  Lancet Neurol       Date:  2005-11       Impact factor: 44.182

Review 9.  Vigabatrin: 2008 update.

Authors:  L James Willmore; Mark B Abelson; Elinor Ben-Menachem; John M Pellock; W Donald Shields
Journal:  Epilepsia       Date:  2009-02       Impact factor: 5.864

10.  Prospective preliminary analysis of the development of autism and epilepsy in children with infantile spasms.

Authors:  Rand Askalan; Mark Mackay; Jessica Brian; Hiroshi Otsubo; Catherine McDermott; Susan Bryson; Jennifer Boyd; Carter Snead; Wendy Roberts; Shelly Weiss
Journal:  J Child Neurol       Date:  2003-03       Impact factor: 1.987

View more
  80 in total

1.  Limiting Retinal Toxicity of Vigabatrin in Children With Infantile Spasms.

Authors:  Prakash Kotagal
Journal:  Epilepsy Curr       Date:  2015 Nov-Dec       Impact factor: 7.500

Review 2.  West Syndrome: A Review and Guide for Paediatricians.

Authors:  Renato D'Alonzo; Donato Rigante; Elisabetta Mencaroni; Susanna Esposito
Journal:  Clin Drug Investig       Date:  2018-02       Impact factor: 2.859

3.  Neonatal hypoglycemic brain injury is a cause of infantile spasms.

Authors:  Guang Yang; Li-Ping Zou; Jing Wang; Xiuyu Shi; Shuping Tian; Xiaofan Yang; Jun Ju; Hongxiang Yao; Yujie Liu
Journal:  Exp Ther Med       Date:  2016-02-25       Impact factor: 2.447

Review 4.  West Syndrome: Questions Aplenty- Few Answers.

Authors:  Shivan Kesavan; Naveen Sankhyan
Journal:  Indian J Pediatr       Date:  2019-01-10       Impact factor: 1.967

5.  Effectiveness and Safety of Different Once-Daily Doses of Adrenocorticotropic Hormone for Infantile Spasms.

Authors:  Jinghua Yin; Qianjin Lu; Fei Yin; Ying Wang; Fang He; Liwen Wu; Lifen Yang; Xiaolu Deng; Chen Chen; Jing Peng
Journal:  Paediatr Drugs       Date:  2017-08       Impact factor: 3.022

Review 6.  Inflammation in Epileptic Encephalopathies.

Authors:  Oleksii Shandra; Solomon L Moshé; Aristea S Galanopoulou
Journal:  Adv Protein Chem Struct Biol       Date:  2017-02-28       Impact factor: 3.507

7.  Epilepsy: Update to guidelines on treatment of infantile spasms.

Authors:  Raili Riikonen
Journal:  Nat Rev Neurol       Date:  2012-08-07       Impact factor: 42.937

Review 8.  Mechanisms of epileptogenesis in pediatric epileptic syndromes: Rasmussen encephalitis, infantile spasms, and febrile infection-related epilepsy syndrome (FIRES).

Authors:  Carlos A Pardo; Rima Nabbout; Aristea S Galanopoulou
Journal:  Neurotherapeutics       Date:  2014-04       Impact factor: 7.620

9.  CPP-115, a vigabatrin analogue, decreases spasms in the multiple-hit rat model of infantile spasms.

Authors:  Stephen W Briggs; Wenzhu Mowrey; Charles B Hall; Aristea S Galanopoulou
Journal:  Epilepsia       Date:  2013-10-28       Impact factor: 5.864

Review 10.  Cognitive and neurodevelopmental comorbidities in paediatric epilepsy.

Authors:  Katherine C Nickels; Michael J Zaccariello; Lorie D Hamiwka; Elaine C Wirrell
Journal:  Nat Rev Neurol       Date:  2016-07-22       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.